Insufficient radiofrequency ablation promotes epithelial–mesenchymal transition mediated by interleukin-6/signal transducer and activator of transcription 3/Snail pathway in the H22 cells

Zhou, Tong; Liu, Bin; Wang, Yongzheng; Wang, Wujie; Chang, Haiyang; Liu, Dong; Li, Yuliang; Song, Zhaomin

doi:10.4103/jcrt.jcrt_12_20

Cited by 10 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RFA is considered to have several advantages, but its application can pose two major problems. First, incomplete RFA can change the characteristics of HCC tissue (e.g., induce epithelial-mesenchymal transition (EMT) of HCC tissue) and induce the recurrence and metastasis of HCC (7,8). Second, the prognosis of HCC patients after RFA is not known (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation

2021

View full text Add to dashboard Cite

Radiofrequency ablation (RFA) is an important strategy for treatment of advanced hepatocellular carcinoma (HCC). However, the prognostic indicators of RFA therapy are not known, and there are few strategies for RFA sensitization. The transcription factor sterol regulatory element binding protein 1 (SREBP)-1 regulates fatty-acid synthesis but also promotes the proliferation or metastasis of HCC cells. Here, the clinical importance of SREBP-1 and potential application of knockdown of SREBP-1 expression in RFA of advanced HCC was elucidated. In patients with advanced HCC receiving RFA, a high level of endogenous SREBP-1 expression correlated to poor survival. Inhibition of SREBP-1 activation using a novel small-molecule inhibitor, SI-1, not only inhibited the aerobic glycolysis of HCC cells, it also enhanced the antitumor effects of RFA on xenograft tumors. Overall, our results: (i) revealed the correlation between SREBP-1 and HCC severity; (ii) indicated that inhibition of SREBP-1 activation could be a promising approach for treatment of advanced HCC.

show abstract